Showing 5671-5680 of 8207 results for "".
- Analysis: Arnica’s Popularity on Social Not Supported by Data for Post-Procedure Recoveryhttps://practicaldermatology.com/news/analysis-arnicas-popularity-on-social-media-outpaces-scientific-support-for-post-procedure-recovery/2475830/Social media users and health care professionals frequently endorse Arnica montana for reducing bruising and swelling following aesthetic injectables, but a recent analysis shows scientific support for its use may be lacking.
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://practicaldermatology.com/news/First-Patient-Dosed-with-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells/2474796/
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Study: Dual-Action Topical Treatment Reduces Lesion Counts in Adult Acne Patientshttps://practicaldermatology.com/news/study-dual-action-topical-treatment-reduces-lesion-counts-adult-acne-patients/2470855/Results from a recent pilot study suggested that a combination therapy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel with clascoterone 1% cream was effective in reducing lesions in adult acne patients. Researchers for the study enrolled 20 adult participants with
- ISHRS to Host 32nd World Congress in Denver This Monthhttps://practicaldermatology.com/news/ishrs-host-32nd-world-congress-denver-month/2468370/From refinements in hair restoration surgical techniques to understanding the psychological and physiological aspects of hair loss, the latest research and concepts in hair growth and restoration will be presented by some of the world’s most renowned hair restoration experts when they convene in
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- Innovent Plans to Submit NDA in China for Plaque Psoriasis Treatment Picankibart Following Phase 3 Datahttps://practicaldermatology.com/news/innovent-plans-submit-nda-china-plaque-psoriasis-treatment-picankibart-following-phase-3-data/2463195/Innovent Biologics announced that picankibart (IBI112) has met all the primary endpoints and key secondary endpoints in the phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis. CLEAR-1 is global the first phase 3 registration study in IL-23p
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w